NASDAQ · CCCC
Healthcare · Biotechnology
$3.21
Down-$0.13 (-3.89%)
Updated Nov 4, 2026, 5:23 PM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CCCC
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
CCCC closed at $3.21 after 21 trading sessions, up 11.46% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $3.27 | $3.42 | $3.17 | $3.21 | 1.59M |
| Nov 2, 2026 | $3.36 | $3.41 | $3.16 | $3.21 | 2.86M |
| Oct 30, 2026 | $3.23 | $3.38 | $3.21 | $3.37 | 2.35M |
| Oct 29, 2026 | $3.41 | $3.44 | $3.20 | $3.30 | 2.72M |
| Oct 28, 2026 | $3.25 | $3.53 | $3.23 | $3.395 | 4.11M |
| Oct 27, 2026 | $2.99 | $3.24 | $2.9501 | $3.21 | 4.12M |
| Oct 26, 2026 | $3.07 | $3.07 | $2.94 | $2.98 | 3.18M |
| Oct 23, 2026 | $3.16 | $3.17 | $3.02 | $3.06 | 4.74M |
| Oct 22, 2026 | $3.13 | $3.25 | $3.12 | $3.18 | 1.69M |
| Oct 21, 2026 | $3.15 | $3.22 | $3.10 | $3.17 | 2.19M |
| Oct 20, 2026 | $2.86 | $3.20 | $2.855 | $3.16 | 3.69M |
| Oct 19, 2026 | $2.80 | $2.94 | $2.80 | $2.89 | 3.11M |
| Oct 16, 2026 | $2.78 | $2.81 | $2.695 | $2.765 | 2.36M |
| Oct 15, 2026 | $2.64 | $2.846 | $2.60 | $2.78 | 3.28M |
| Oct 14, 2026 | $2.72 | $2.795 | $2.59 | $2.61 | 3.1M |
| Oct 13, 2026 | $3.04 | $3.06 | $2.75 | $2.78 | 3.82M |
| Oct 12, 2026 | $3.16 | $3.30 | $3.05 | $3.06 | 1.5M |
| Oct 9, 2026 | $3.00 | $3.1899 | $2.95 | $3.16 | 2.51M |
| Oct 8, 2026 | $2.80 | $2.88 | $2.7211 | $2.85 | 2.83M |
| Oct 7, 2026 | $2.85 | $2.95 | $2.82 | $2.82 | 2.27M |
| Oct 6, 2026 | $3.02 | $3.03 | $2.79 | $2.88 | 2.11M |
The latest Smart Investors Daily articles mentioning CCCC.
Company
Market Activity
Research & News
CCCC research
Company profile and research snapshot.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 28, 2026 | Lake Street | Buy | — |
| Oct 9, 2026 | JP Morgan | Overweight | — |
| Jun 1, 2026 | Evercore ISI Group | Outperform | — |
| Feb 27, 2026 | Barclays | Overweight | — |
| Feb 23, 2026 | Brookline Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 28, 2026
Lake Street analyst Chad Messer initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Buy rating and announces Price Target of $11.
Yahoo · Oct 20, 2026
Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the appointment of Paul Hudson and Utpal Koppikar as independent members of its Board of Directors, effective immediately. The additions bring deep expertise in global biopharma leadership, commercial strategy, and financial management to Insmed's Board as the Company continues to adv
Benzinga · Oct 9, 2026
JP Morgan analyst Anupam Rama initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Overweight rating and announces Price Target of $10.
Yahoo · Oct 9, 2026
Here is how MacroGenics (MGNX) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CCCC.
